NCT04652648 is a Phase 4 clinical trial of Hydroxychloroquine in Covid19, sponsored by Bryn Mawr Hospital.

Who is sponsoring NCT04652648?

NCT04652648 is sponsored by Bryn Mawr Hospital.

What drugs are being tested in NCT04652648?

Interventions in NCT04652648: Hydroxychloroquine.

What condition does NCT04652648 study?

NCT04652648 studies Covid19, Hydroxychloroquine, Coronavirus Infection, Transmission, Prophylaxis.

Is NCT04652648 still recruiting?

NCT04652648 is currently completed. Last updated 3 December 2020.

Last reviewed 2020-12-03 · How we verify

NCT04652648

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts

Completed Phase 4 Last updated 3 December 2020

What this trial tests

Phase 4 trial testing Hydroxychloroquine in Covid19 in 54 participants. Completed in 15 November 2020.

Timeline

27 May 2020

Primary endpoint
31 October 2020

15 November 2020

Quick facts

Lead sponsor	Bryn Mawr Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	54
Start date	27 May 2020
Primary completion	31 October 2020
Estimated completion	15 November 2020
Sites	3 locations across United States

Drugs / interventions tested

Hydroxychloroquine (HYDROXYCHLOROQUINE) — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →
Hydroxychloroquine — all drugs for Hydroxychloroquine →
Coronavirus Infection — all drugs for Coronavirus Infection →
Transmission — all drugs for Transmission →

Sponsor

Bryn Mawr Hospital

Who can join

18 and older, any sex, with Covid19 or Hydroxychloroquine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

* organizing an entirely no in-person contact clinical trial is feasible during a 22 COVID-19 pandemic 23 * Remote smartphone 6-lead ECG monitoring is possible even in a group unfamiliar 24 with the technology 25 * Hydroxychloroquine used prophylactically at 200 mg BID had no observable 26 cardiotoxicity 27 * Additional study using this technique is warranted to look at reliability and cost-28 effectiveness

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Testing the feasibility of operationalizing a prospective, randomized trial with remote cardiac safety EKG monitoring during a pandemic.
Liu HH, Ezekowitz MD, Columbo M, Khan O, et al · · 2022 · cited 10× · PMID 34037911 · DOI 10.1007/s10840-021-00989-x
The future is now: our experience starting a remote clinical trial during the beginning of the COVID-19 pandemic.
Liu HH, Ezekowitz MD, Columbo M, Khan O, et al · · 2021 · cited 4× · PMID 34493311 · DOI 10.1186/s13063-021-05537-6

Verify or expand the search:

Other trials of Hydroxychloroquine

Trials testing the same drug.

NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07343635 — The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined · NA · recruiting
NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT06971744 — Autophagy Maintenance (AUTOMAIN) · Phase 2 · recruiting
NCT05841758 — Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis · Phase 4 · recruiting

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04652648 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bryn Mawr Hospital
Last refreshed: 3 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04652648.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing